HomeComparePTKFF vs PFE

PTKFF vs PFE: Dividend Comparison 2026

PTKFF yields 3.72% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $10.3K in total portfolio value· pulled ahead in Year 10
10 years
PTKFF
PTKFF
● Live price
3.72%
Share price
$0.06
Annual div
$0.00
5Y div CAGR
19.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$39.3K
Annual income
$3,967.70
Full PTKFF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PTKFF vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPTKFFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PTKFF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PTKFF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PTKFF
Annual income on $10K today (after 15% tax)
$316.37/yr
After 10yr DRIP, annual income (after tax)
$3,372.54/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $18,947.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PTKFF + PFE for your $10,000?

PTKFF: 50%PFE: 50%
100% PFE50/50100% PTKFF
Portfolio after 10yr
$44.4K
Annual income
$15,113.21/yr
Blended yield
34.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PTKFF
No analyst data
Altman Z
8.5
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PTKFF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPTKFFPFE
Forward yield3.72%6.13%
Annual dividend / share$0.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR19.5%13.2%
Portfolio after 10y$39.3K$49.6K
Annual income after 10y$3,967.70$26,258.71
Total dividends collected$16.2K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PTKFF vs PFE ($10,000, DRIP)

YearPTKFF PortfolioPTKFF Income/yrPFE PortfolioPFE Income/yrGap
1$11,145$444.78$9,153$693.39+$2.0KPTKFF
2$12,479$553.61$8,593$849.25+$3.9KPTKFF
3$14,044$692.28$8,336$1,066.78+$5.7KPTKFF
4$15,898$870.16$8,437$1,384.80+$7.5KPTKFF
5$18,110$1,100.06$9,013$1,875.40+$9.1KPTKFF
6$20,778$1,399.58$10,306$2,680.72+$10.5KPTKFF
7$24,026$1,793.30$12,820$4,101.38+$11.2KPTKFF
8$28,023$2,315.85$17,673$6,826.70+$10.3KPTKFF
9$33,001$3,016.74$27,543$12,591.86+$5.5KPTKFF
10← crossover$39,279$3,967.70$49,560$26,258.71$10.3KPFE

PTKFF vs PFE: Complete Analysis 2026

PTKFFStock

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Full PTKFF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PTKFF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PTKFF vs SCHDPTKFF vs JEPIPTKFF vs OPTKFF vs KOPTKFF vs MAINPTKFF vs JNJPTKFF vs MRKPTKFF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.